Lifevantage Corp Stock Price, News & Analysis

LifeVantage (Nasdaq:LFVN) has announced a strategic acquisition of LoveBiome, a direct sales company specializing in microbiome health solutions. The acquisition strengthens LifeVantage's position in the rapidly growing gut health market, which is projected to expand from $14.4 billion in 2025 to $32.4 billion by 2035.

The deal centers around LoveBiome's P84 product, which focuses on gut health regulation and restoration through Activation technology, complementing LifeVantage's existing portfolio including Protandim® and MindBody GLP-1 System™. The transaction is expected to close by mid-October 2025 and will be accretive to Adjusted EPS and EBITDA in the first year.

LifeVantage (Nasdaq: LFVN), a health and wellness company focused on cellular health products, has announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025, in New York, NY.

President and CEO Steve Fife, along with CFO Carl Aure, will conduct investor meetings and deliver a presentation on Wednesday, September 10, 2025, at 1:00 p.m. Eastern Time. The presentation will be available via live webcast on the company's investor relations website, with a replay accessible for approximately 90 days afterward.

LifeVantage (Nasdaq:LFVN), a health and wellness company focused on cellular health products, has announced a quarterly cash dividend of $0.045 per share. The dividend will be paid on September 16, 2025, to stockholders of record as of September 8, 2025.

LifeVantage (Nasdaq:LFVN), a health and wellness company focused on cellular-level health products, has scheduled its fourth quarter and full fiscal year 2025 financial results announcement for September 4, 2025, after market close.

The company will host a conference call for investors at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time). U.S. participants can dial (877) 704-4453, while international callers should use (201) 389-0920. A replay will be available until September 18, 2025. A live webcast will be accessible through the company's Investor Relations website, with a 30-day archive period.

LifeVantage (Nasdaq: LFVN) announced its planned expansion into Iceland, set to launch in September 2025. The company will introduce a select portfolio of its wellness products, including its flagship Protandim Nrf2 Synergizer, MindBody GLP-1 System, TrueScience Liquid Collagen, and LifeVantage ProBio.

The expansion includes three wellness product stacks: Healthy Glow Essentials Stack, Healthy Weight Stack, and Premium Stack. Alongside the product launch, LifeVantage will introduce its business opportunity through the Evolve Compensation Plan, allowing local entrepreneurs to join as Consultants.

LifeVantage (Nasdaq: LFVN) has announced expanded clinical trial results for its MindBody GLP-1 System™, showing enhanced effectiveness in natural GLP-1 production. The combined data from trials completed in April 2025 and fall 2024 demonstrated an average increase in GLP-1 of over 200%, up from the previously reported 140%.

The clinical studies revealed significant outcomes including average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds. Key body composition improvements include up to 9% decrease in total body fat, 24% decrease in visceral fat, and 6% increase in skeletal muscle. Notably, 100% of weight lost was from fat, not muscle.

Participants reported substantial behavioral changes, with 95% experiencing decreased sugar cravings and over 85% reporting improved eating habits and reduced hunger. The company also completed an independent 12-week trial of the international formula (MB System) with similar positive results.

LifeVantage (Nasdaq: LFVN) hosted its global Activate 2025 virtual event, introducing the new "Summer in the Fast Lane" campaign and quarterly business initiative. The company unveiled a new High Speed Health Stack featuring MindBody GLP-1 System, Protandim Nrf2 Synergizer, PhysIQ Fat Burn, and a complimentary Protandim NAD Synergizer.

The campaign is part of a new quarterly business strategy designed to drive growth through focused sales sprints and includes incentives such as mini trips worldwide. The company also announced its upcoming U.S. Momentum Academy event scheduled for October 23-25 in Dallas, TX, which will offer in-person training and networking opportunities.

LifeVantage Corporation (LFVN), a health and wellness company, has announced a quarterly cash dividend of $0.045 per share of common stock. The dividend represents a 12.5% increase from the previous quarter. The dividend will be paid on June 13, 2025, to stockholders of record at the close of business on May 30, 2025. LifeVantage specializes in products designed to activate optimal health processes at the cellular level.

LifeVantage (LFVN) reported strong Q3 fiscal 2025 results with revenue reaching $58.4 million, up 21.1% year-over-year. Net income per diluted share doubled to $0.26 from $0.13 in the prior year. The Americas region showed robust growth of 29.5%, while Asia/Pacific & Europe saw a 7.2% decline. Gross profit margin improved by 210 basis points to 81.0%. The company's MindBody GLP-1 System™ drove strong demand, and international expansion continued with launches in multiple Asian and European markets. The company declared a dividend of $0.045 per share and maintained its fiscal 2025 guidance with expected revenue between $228-235 million and adjusted EBITDA of $21-24 million.

Key metrics include adjusted EBITDA of $6.4 million (vs $5.1M year ago), cash and equivalents of $22.5 million with no debt, and operating income of $4.1 million (vs $1.9M year ago).